This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Otsuka Holdings Co., Ltd.
Drug Names(s): OTS102, OTS-102
Description: Elpamotide (OTS-102) is a VEGFR-2 peptide designed to act as a cancer vaccine by eliciting an immune response against that angiogenesis target.
Otsuka, OncoTherapy, and Fuso
In January 2008, Otsuka Pharmaceutical obtained the exclusive rights from OncoTherapy Science to develop, manufacture and commercialize several therapeutic peptide vaccines for pancreatic cancer, including OTS11101.
In January 2010, Otsuka Pharmaceutical and Fuso Pharmaceutical concluded an agreement on the manufacturing and commercialization in Japan of a therapeutic cancer vaccine OTS102, which is expected to inhibit angiogenesis. Under the terms of agreement, Fuso, which was granted the exclusive rights to manufacture and commercialize OTS102 in Japan from OncoTherapy Science, has sublicensed the manufacturing and commercialization rights to Otsuka Pharmaceutical. Otsuka Pharmaceutical shall pay Fuso an upfront payment as well as milestone payments and royalties. With the agreement reached this time, Otsuka Pharmaceutical has obtained additional rights to manufacture and commercialize OTS102 in Japan.
In January 2015,...See full deal structure in Biomedtracker
Partners: Fuso Pharmaceuticals
Additional information available to subscribers only: